ArticleJournal of neurology, neurosurgery, and psychiatry2006
Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer.
Article in Journal of neurology, neurosurgery, and psychiatry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 69 citations in OpenAlex.
- Consensus Paper: Latent Autoimmune Cerebellar Ataxia (LACA).Cerebellum (London, England) · 2024Article
- Autoimmune cerebellar ataxia associated with anti-Purkinje cells antibodies: the next frontier of neuroimmunology.Annals of translational medicine · 2023Review
- Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia.Journal of neuroinflammation · 2023Article
- Paraneoplastic Neurologic Disorders.Current neurology and neuroscience reports · 2023Review
- Rare Etiologies in Immune-Mediated Cerebellar Ataxias: Diagnostic Challenges.Brain sciences · 2022Review
- Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses.Cerebellum (London, England) · 2022Review
- Inositol 1,4,5-trisphosphate receptor type 1 autoantibody (ITPR1-IgG/anti-Sj)-associated autoimmune cerebellar ataxia, encephalitis and peripheral neuropathy: review of the literature.Journal of neuroinflammation · 2022Review
- Update on Paraneoplastic Cerebellar Degeneration.Brain sciences · 2021Review
- Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis.Brain : a journal of neurology · 2021Article
- Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome.Journal of clinical neurology (Seoul, Korea) · 2020Review
- Treatment of Cerebellar Ataxia in the Context of Systemic Diseases.Current treatment options in neurology · 2017Review
- Detection of brain-directed autoantibodies in the serum of non-small cell lung cancer patients.PloS one · 2017Article
- Update on neurological paraneoplastic syndromes.Current opinion in oncology · 2015Review
- Clinico-pathological correlation in adenylate kinase 5 autoimmune limbic encephalitis.Journal of neuroimmunology · 2015Article
- 'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC.Journal of neuroinflammation · 2015Review
- 'Medusa-head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII.Journal of neuroinflammation · 2015Review
- Antibodies to the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in cerebellar ataxia.Journal of neuroinflammation · 2014Article
- Paraneoplastic syndromes associated with lung cancer.World journal of clinical oncology · 2014Review
- Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia.Journal of neuroinflammation · 2013Article
- Diagnostic Approach to a Patient With Paraneoplastic Neurological Syndrome.World journal of oncology · 2012Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
Abstract
backgroundThe clinical and immunological profiles of patients with paraneoplastic cerebellar degeneration (PCD) and non-small-cell lung cancer (NSCLC) are not well known.
objectiveTo review the clinical and immunological features of patients with PCD, NSCLC and without well-characterised onconeural antibodies.
methodsThe clinical features of nine patients with the diagnosis of classical PCD and NSCLC, included in our archives, were retrospectively reviewed. The presence of antibodies to cerebellar components was determined by immunohistochemistry and immunoblot of rat cerebellum. A cDNA library of human cerebellum was screened with the positive sera to identify the antigen.
resultsNine patients with PCD and NSCLC were identified. Six patients were men, and the median age at diagnosis of PCD was 63 (range 47-73) years. PCD was completely reversed in two patients, and partially in one, after treatment of the tumour. The serum of one of the patients with PCD showed a unique reactivity with Purkinje cells. The screening of a cerebellar-expression library resulted in the isolation of protein kinase Cgamma (PKCgamma). PKCgamma immunoreactivity was not observed in the serum of 170 patients with non-paraneoplastic neurological syndromes, 27 patients with PCD, no onconeural antibodies and small-cell lung cancer, and 52 patients with NSCLC without paraneoplastic neurological syndromes. The NSCLC from 11 patients without PCD did not express PKCgamma at either the RNA or protein level. However, many cells of the NSCLC of the patient with PKCgamma antibodies expressed PKCgamma.
conclusionPCD occurs in patients with NSCLC without typical onconeural antibodies and is associated with immune reactions against key proteins of the Purkinje cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.